Ultimately there is no one size fits all approach
These may occur if: The injection was too shallow or too deep The fluid volume was too high for the site The product was too concentrated or acidic Local immune cells formed a small granuloma (harmless but annoying) Applying a warm compress can help disperse the fluid and reduce the lump
We chase a goal through several pathways at once, which is also why we may pair GHK-Cu with something like MOTS-C that works the energy side of the cell
its up to the FDA, and right now, these specific peptides sit outside it. The biggest risk to this potential pathway, Robinson explains, is reporting of adverse events, which the FDA describes as any undesirable experience associated with the use of a medical product in a patient. Should an adverse event happen, Robinson says it could negatively impact or delay the rulemaking process. As the FDA pointed out in their official meeting recommendation to keep the peptides under their current restrictions, these peptides simply dont have adequate clinical data behind them
[33] Pernicious anemia can contribute to a delay in physical growth in children, and may also be a cause for delay in puberty for adolescents
Davies M, Frch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al